PMID- 6695853
OWN - NLM
STAT- MEDLINE
DCOM- 19840323
LR  - 20190904
IS  - 0277-3732 (Print)
IS  - 0277-3732 (Linking)
VI  - 7
IP  - 1
DP  - 1984 Feb
TI  - Large mediastinal mass in Hodgkin's disease. Results of two treatment modalities.
PG  - 65-73
AB  - Sixty-eight untreated patients with Hodgkin's disease (HD), stages I-III, 
      presenting with a large mediastinal mass were treated as follows: patients with 
      "good-risk HD" (lymphocyte predominant or nodular sclerosis and no "B" symptoms) 
      stages I and II were treated by randomization with involved field radiotherapy 
      (IF RT) or IF RT plus six cycles of combination chemotherapy (CT). Those with 
      "poor-risk HD" (presence of B symptoms or with other histologic types) stages I 
      and II and all patients with stage III were treated by randomization with total 
      nodal radiation (TNR) or TNR + CT. Complete remission (CR) was achieved in 66/68 
      patients (97%) with the initial RT. A significantly longer duration of remission 
      (p = 0.001), but not of survival (p = 0.08) was observed in patients treated with 
      RT + CT compared to RT alone. Significantly longer duration of remission (p = 
      0.01), but not of survival, was observed in patients with good-risk stages I-II 
      treated with RT + CT. In this category, remission and survival was better with RT 
      + CT than with RT alone in stage III, but these differences were not 
      statistically significant. In poor-risk patients stages I-II, a trend for longer 
      remission and survival (not significant) was observed in patients treated with RT 
      + CT; in stage III, both treatment modalities gave similar poor results. Both 
      treatment modalities were well tolerated by most patients. One patients died with 
      radiation pneumonitis shortly after completion of TNR. One patient developed a 
      malignant schwannoma after treatment with IF RT, and another one developed acute 
      nonlymphocytic leukemia after TNR + CT. Decrease in the transverse diameter of 
      the heart without overt manifestations of cardiac disease was observed in 59% of 
      the patients evaluated for this parameter.
FAU - Gomez, G A
AU  - Gomez GA
FAU - Panahon, A M
AU  - Panahon AM
FAU - Stutzman, L
AU  - Stutzman L
FAU - Moayeri, H
AU  - Moayeri H
FAU - Park, J J
AU  - Park JJ
FAU - Barcos, M
AU  - Barcos M
FAU - Kim, U
AU  - Kim U
FAU - Han, T
AU  - Han T
FAU - Henderson, E S
AU  - Henderson ES
LA  - eng
GR  - CA-5834/CA/NCI NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Clin Oncol
JT  - American journal of clinical oncology
JID - 8207754
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Combined Modality Therapy
MH  - Female
MH  - Hodgkin Disease/mortality/*therapy
MH  - Humans
MH  - Male
MH  - Mediastinal Neoplasms/mortality/*therapy
MH  - Middle Aged
MH  - Myocardium/pathology
MH  - Neoplasm Staging
MH  - Prospective Studies
MH  - Random Allocation
MH  - Risk
MH  - Time Factors
EDAT- 1984/02/01 00:00
MHDA- 1984/02/01 00:01
CRDT- 1984/02/01 00:00
PHST- 1984/02/01 00:00 [pubmed]
PHST- 1984/02/01 00:01 [medline]
PHST- 1984/02/01 00:00 [entrez]
AID - 10.1097/00000421-198402000-00009 [doi]
PST - ppublish
SO  - Am J Clin Oncol. 1984 Feb;7(1):65-73. doi: 10.1097/00000421-198402000-00009.